The use of delamanid in the treatment of multidrug-resistant tuberculosis: interim policy guidance
The aim of this guidance is to provide the interim principles that should guide the use of delamanid in conjunction with WHO-recommended MDR-TB treatment. It also specifies the essential treatment and management conditions for use of this drug, in particular the patient's eligibility criteria and safety ...
Analyse coût-bénéfice, Tuberculose multirésistante/traitement médicamenteux, Association de médicaments, Nitroimidazoles/usage thérapeutique, Résultat thérapeutique, Antituberculeux/usage thérapeutique, Tuberculose pulmonaire/traitement médicamenteux, Essais cliniques comme sujet, Nitroimidazoles/économie, Antituberculeux/économie